VISEN Pharmaceuticals
The company operates in the healthcare diagnostics segment, focusing on biotechnology and medical research, and generates revenue primarily through the development and sale of diagnostic products and services.
Business. 2561.HK is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the Hong Kong Stock Exchange under the ticker 2561.HK. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
2561.HK is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, generating revenue through product sales. It is listed on the Hong Kong Stock Exchange under the ticker 2561.HK. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
The company has a market capitalization of 2,599,811,036.48 CNY, with a market price of 22.82 CNY per share. The shares outstanding are 113,926,864 for both basic and diluted shares, indicating no dilution from stock options or convertible securities. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.
Profitability and return metrics are not available in the provided data, making it difficult to compare the company's performance against industry_config preferred metrics or cohort medians. Without these metrics, an assessment of the company's efficiency and profitability relative to its peers cannot be made.
The company's segments and geographic exposure are not disclosed in the available data, which limits the ability to assess revenue concentration or geographic diversification. This lack of information also prevents a detailed analysis of the company's exposure to regional economic conditions or regulatory environments.
The company's growth trajectory is not quantified in the provided data, as there are no numeric deltas or revenue history available. Analysts have provided a mean price target of 66.00 CNY, with a median of 66.00 CNY, suggesting a potential for significant appreciation in the stock price. However, the mean recommendation is 2.00, indicating a "buy" rating, with one buy recommendation and no strong buy or hold ratings.
Risk factors include the inability to assess liquidity risk, which could affect the company's ability to meet short-term obligations. The dilution risk is currently low, as there is no evidence of dilution from stock options or convertible securities. No adjustments have been applied to the valuation metrics, and no specific risk factors are detailed in the source documents.
Recent events, such as filings or transcripts, are not provided in the available data, which limits the ability to assess the company's recent performance or strategic direction. The absence of such information also prevents an evaluation of management's guidance or investor sentiment based on recent communications.
- The company is classified in the Biotechnology & Medical Research industry with a high confidence level.
- The company's market capitalization is 2,599,811,036.48 CNY, with a market price of 22.82 CNY per share.
- Analysts have provided a mean price target of 66.00 CNY, suggesting potential for significant appreciation.
- The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs.
- The company's growth trajectory and profitability metrics are not available in the provided data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -2,43 |
| Revenue | —no estimate | —no estimate | 421,6M CNY |
| Operating income | —no estimate | —no estimate | -283,9M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 2561.HK Market data — financials · 2026-05-26
- VISEN Pharmaceuticals Market data — analyst estimates · 2026-05-26